Lupin's Goa facility receives seven FDA observations

Lupin Limited reported that a U.S. FDA inspection at its Goa, India, manufacturing facility, conducted from November 10 to November 21, 2025, concluded with the issuance of a Form-483 citing seven observations.

The company has committed to addressing these observations and submitting a response to the U.S. FDA within the specified timeframe. Lupin reaffirmed its dedication to maintaining compliance with CGMP standards across all its facilities.

This disclosure was made pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.